Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2025 Financial Results The Company reported a net loss for the first quarter of 2025 of $29.3 million, or$0.46 per share, compared to a net loss of $14.7 million, or$0.27 per share, for the first quarter of 2024. Bala Cynwyd, PA, April 30, 2025 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2025 operating and fin ...